ALK-Abelló A/S
Clinical trials sponsored by ALK-Abelló A/S, explained in plain language.
ALK-Abelló A/S
ALK-B
COPENHAGEN
A pharmaceutical company specializing in allergy immunotherapy.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New allergy tablet could help millions breathe easier Results expected Sep 2026 (estimated)